Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-121 in Healthy Subjects and Cystic Fibrosis
NCT03768089Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of vanzacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Mar 2018; status: completed.
02
Drugs
vanzacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03768089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03768089.